OBJECTIVETo investigate the protective effects of putative AGEs (advanced glycation endproducts) inhibitor salidroside against aging in an accelerated mouse aging model induced by D-galactose.

METHODSA group of 5-month-old C57BL/6J mice were treated daily with D-galactose, D-galactose combined with salidroside, salidroside alone, and control buffer for 8 weeks. At the end of the treatment, serum AGEs levels, neurological activities, expression of glial fibrillary acidic protein (GFAP) and neurotrophin-3 (NT-3) in the cerebral cortex, as well as lymphocyte proliferation and IL-2 production were determined.

RESULTSD-galactose induced mouse aging model was developed as described before. As expected, salidroside blocked D-galactose induced increase of serum AGEs levels. It also reversed D-galactose induced aging effects in neural and immune system, as evidenced by improving motor activity, increasing memory latency time, and enhancing lymphocyte mitogenesis and interleukin-2 (IL-2) production. Furthermore, elevated expression of GFAP and NT-3 in the aged model mice was also reduced upon salidroside treatment.

CONCLUSIONSalidroside inhibits AGEs formation in vivo, which at least partially contributes to its anti-aging effect in D-galactose induced aging model.

Aging, Premature ; blood ; chemically induced ; prevention & control ; Animals ; Cerebral Cortex ; metabolism ; Drugs, Chinese Herbal ; pharmacology ; therapeutic use ; Galactose ; Glial Fibrillary Acidic Protein ; Glucosides ; pharmacology ; therapeutic use ; Glycation End Products, Advanced ; blood ; Interleukin-2 ; metabolism ; Memory ; drug effects ; Mice ; Mice, Inbred C57BL ; Motor Activity ; drug effects ; Nerve Growth Factors ; metabolism ; Nerve Tissue Proteins ; metabolism ; Phenols ; pharmacology ; therapeutic use ; Spleen ; drug effects ; immunology ; T-Lymphocytes ; drug effects